Ipsen (OTCMKTS:IPSEY) Price Target Raised to €100.00 at Credit Suisse Group

Ipsen (OTCMKTS:IPSEYGet Rating) had its price target lifted by Credit Suisse Group from €95.00 ($97.94) to €100.00 ($103.09) in a report published on Monday, The Fly reports.

IPSEY has been the topic of several other reports. Barclays raised their price objective on Ipsen from €88.00 ($90.72) to €95.00 ($97.94) and gave the company an underweight rating in a research note on Thursday, April 14th. Societe Generale lifted their price objective on Ipsen from €112.00 ($115.46) to €120.00 ($123.71) and gave the stock a buy rating in a research note on Friday, April 29th. UBS Group cut their price objective on Ipsen from €117.00 ($120.62) to €102.00 ($105.15) and set a neutral rating on the stock in a research note on Wednesday, July 20th. Finally, Bryan, Garnier & Co downgraded Ipsen from a buy rating to a neutral rating in a report on Wednesday, April 27th. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Ipsen presently has a consensus rating of Hold and a consensus target price of $104.25.

Ipsen Stock Down 6.1 %

OTCMKTS:IPSEY opened at $24.13 on Monday. The stock’s 50-day simple moving average is $23.77 and its 200 day simple moving average is $26.33. Ipsen has a twelve month low of $21.17 and a twelve month high of $32.51.

Ipsen Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, June 9th. Stockholders of record on Wednesday, June 1st were issued a dividend of $0.2269 per share. The ex-dividend date of this dividend was Tuesday, May 31st. This represents a dividend yield of 0.88%.

Ipsen Company Profile

(Get Rating)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents.

Featured Articles

The Fly logo

Analyst Recommendations for Ipsen (OTCMKTS:IPSEY)

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.